Immunomodulator

T-cells (represented by objects labeled as 't') are removed from the patient's blood.Then in a lab setting the gene that encodes for the specific antigen receptors are incorporated into the T-cells.Thus producing the CAR receptors (labeled as c) on the surface of the cells.The newly modified T-cells are then further harvested and grown in the lab.After a certain time period, the engineered T-cells are infused back into the patient. Immunotherapy, also known asbiological therapyorbiotherapy, encompasses a diverse set of therapeutic strategies that harness or modify theimmune systemto prevent, control, or eliminate disease.​​​‍​​‍​​​​‍​​‍‍ In its narrowest definition, immunotherapy refers to treatments designed to stimulate or guide the immune system to recognize and fight cancer, often by enhancing or restoring immune responses to eradicate malignant cells while sparing healthy tissue. A broader definition of immunotherapy applies beyond oncology, including strategies to stimulate or suppress immune activity against other diseases such asautoimmune disorders,infectious diseases, andallergies. These approaches may involvevaccines,immune modulators, ormonoclonal antibodiesdesigned to alter immune responses, either to boost protection against pathogens or to reduce damaging inflammation. Immunotherapy includes both passive methods, like monoclonal antibodies that mark abnormal cells for immune destruction, and active methods, such as cancer vaccines, immune checkpoint inhibitors, adoptive cell transfer, and cytokine therapies. Advances in immunotherapy have transformed the treatment landscape for cancer and are increasingly applied to a wider range of conditions, improving outcomes for many patients, though responses can vary depending on disease type, genetic background, and environmental factors. Cell-based immunotherapies are effective for some cancers.Immune effector cells such aslymphocytes,macrophages,dendritic cells,natural killer cells, andcytotoxic T lymphocyteswork together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells. Vaccine-induced immunity to COVID-19 relies mostly on an immunomodulatory T-cell response. Therapies such asgranulocyte colony-stimulating factor(G-CSF),interferons,imiquimodand cellular membrane fractions frombacteriaare licensed for medical use. Others includingIL-2,IL-7,IL-12, variouschemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides andglucansare involved in clinical and preclinical studies.